van der Heijde, Desirée http://orcid.org/0000-0002-5781-158X
Schiff, Michael
Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Xie, Li
Meszaros, Gabriella
Ishii, Taeko
Casillas, Marta
Ortmann, Robert A
Emery, Paul
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
https://doi.org/10.1136/annrheumdis-2018-213271
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276
AB0258 Impact of controlling disease activity on regaining normal physical function, and achieving no or limited pain in patients with rheumatoid arthritis treated with baricitinib
https://doi.org/10.1136/annrheumdis-2018-eular.1995
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
https://doi.org/10.1136/rmdopen-2020-001370
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
https://doi.org/10.1136/annrheumdis-2016-210094
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
https://doi.org/10.1136/annrheumdis-2017-212461
AB0281 Characterization of changes in lymphocyte subsets in baricitinib-treated patients with early, dmard naÏve, rheumatoid arthritis in a phase 3 study
https://doi.org/10.1136/annrheumdis-2017-eular.1336
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-000898
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison
https://doi.org/10.1136/rmdopen-2019-001131
Robust analyses for radiographic progression in rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2022-002543
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
https://doi.org/10.1136/rmdopen-2021-001994
Documents that mention this clinical trial
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
https://doi.org/10.1136/annrheumdis-2018-213271
Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
https://doi.org/10.1136/annrheumdis-2018-214261
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
https://doi.org/10.1136/rmdopen-2020-001370
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
https://doi.org/10.1136/annrheumdis-2016-210094
THU0114 Effects of smoking on baricitinib efficacy in patients with rheumatoid arthritis: pooled analysis from two phase 3 clinical trials
https://doi.org/10.1136/annrheumdis-2017-eular.1341
Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
https://doi.org/10.1136/rmdopen-2017-000581
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
https://doi.org/10.1136/rmdopen-2018-000662
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
https://doi.org/10.1136/annrheumdis-2017-212461
Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study
https://doi.org/10.1007/s40744-021-00317-9
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-000898
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2016-000410
Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2017-000546
Documents that mention this clinical trial
THU0078 Concomitant use of conventional synthetic dmards and response to baricitinib
https://doi.org/10.1136/annrheumdis-2017-eular.1342
Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis
https://doi.org/10.1007/s40744-018-0110-x
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
https://doi.org/10.1136/annrheumdis-2018-213271
Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
https://doi.org/10.1136/annrheumdis-2018-214261
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
https://doi.org/10.1136/annrheumdis-2017-211259
AB0287 BENEFITS OF PAIN RELIEF ON FATIGUE, FUNCTION, AND QUALITY OF LIFE WHEN JOINT INFLAMMATION IS CONTROLLED IN PATIENTS WITH RA
https://doi.org/10.1136/annrheumdis-2019-eular.542
AB0258 Impact of controlling disease activity on regaining normal physical function, and achieving no or limited pain in patients with rheumatoid arthritis treated with baricitinib
https://doi.org/10.1136/annrheumdis-2018-eular.1995
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-214529
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
https://doi.org/10.1136/annrheumdis-2016-210094
POS0646 RAPID AND CONCURRENT IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES OF RHEUMATOID ARTHRITIS WITH BARICITINIB IN RA-BEAM
https://doi.org/10.1136/annrheumdis-2021-eular.65
POS0649 BARICITINIB PROVIDES GREATER IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES ACROSS ALL DISEASE ACTIVITY LEVELS COMPARED TO PLACEBO AND ADALIMUMAB IN RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.182
P092 Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis from a phase 3 study
https://doi.org/10.1136/annrheumdis-2018-ewrr2018.108
THU0114 Effects of smoking on baricitinib efficacy in patients with rheumatoid arthritis: pooled analysis from two phase 3 clinical trials
https://doi.org/10.1136/annrheumdis-2017-eular.1341
Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
https://doi.org/10.1136/rmdopen-2017-000581
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
https://doi.org/10.1136/annrheumdis-2017-212461
FRI0048 NUMBER NEEDED TO TREAT TO ACHIEVE MINIMUM CLINICALLY SIGNIFICANT DIFFERENCES IN PATIENT-REPORTED OUTCOMES IN PATIENTS TREATED WITH BARICITINIB
https://doi.org/10.1136/annrheumdis-2020-eular.1440
SAT0055 Baricitinib showed rapid and greater reduction in pain compared to adalimumab or placebo in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1346
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-000898
Robust analyses for radiographic progression in rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2022-002543
Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2017-000546
Documents that mention this clinical trial
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
https://doi.org/10.1136/annrheumdis-2018-213271
Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib
https://doi.org/10.1136/annrheumdis-2018-214261
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2018-214529
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
https://doi.org/10.1136/annrheumdis-2016-210094
Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
https://doi.org/10.1136/rmdopen-2018-000662
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
https://doi.org/10.1136/annrheumdis-2017-212461
Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study
https://doi.org/10.1007/s40744-021-00317-9
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-000898
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2019-001095
Funding for this research was provided by:
Incyte Corporation
Eli Lilly and Company